After receiving $100 million in financing, Rongchang Bio's fusion protein TACI-Fc treatment of lupus lupus gets FDA fast-track designation
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
RemeGen announced that the U.SFood and Drug Administration (FDA) has granted fast-track designations for its new recombinant TACI-Fc fusion protein RC18 to treat systemic lupus erythematosus (SLE)With its novel two-target mechanism, RC18 showed a statistically significant improvement in patientsRC18 is a new recombinant TACI-Fc (cross-membrane activator and calcium-to-procycline ligand interaction molecule) fusion protein for the treatment of autoimmune diseasesRC18 has a dual targeting mechanism that inhibits the development and survival of pulp cells and mature B cells associated with a variety of autoimmune diseasesRC18 works by binding to two cellular signaling molecules: B lymphocytic stimulator (BLyS) and proliferation-induced ligand (APRIL)currently, RC18 is being studied in a number of late-stage clinical trials of autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis and optic neurospinalitisDr Kenmin Fang, founder and CEO of RemeGen, said: 'SLE is a chronic autoimmune disease that attacks healthy tissues and is estimated to affect between 322,000 and 1.5 million people in the United StatesPatients have very limited treatment options available, and fast-track designations give RemeGen the opportunity to help those affected by the disease by providing advanced therapiesTheRemeGen's recently completed $100 million financing, led by Lilly Asia Ventures and Blue Lake Capital
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.